Hørsholm, Denmark, 21 October 2019 – Oncology Venture A/S (“OV” or the “Company”) today announced that the board of directors of the Company has resolved on a rights issue of shares supported by an authorization granted to the board of directors at an Extra General Meeting on 15 October 2019. Oncology Venture is also today publishing a prospectus (the “Prospectus”) which has been prepared in connection with the rights issue in the Company of up to a maximum of 50,341,080 offer units. Each unit (“Offer Unit”) consists of one (1) new share of nominal DKK 0.05 (“New Share”) with one (1) warrant attached which confers the right to subscribe one (1) share of nominal DKK 0.05 share in the Company at an exercise price of SEK 6.00 (“Investor Warrant”). New Shares are subscribed against cash payment of SEK 2. Investor Warrants are subscribed without payment. Guarantees and undertakings of SEK 100 million from underwriters have been received.
Oncology Venture invites its shareholders and the public to a press meeting with the Company’s new CEO, Steve Carchedi, on Friday 25 October 2019 at 14:00 (CEST) for a presentation of the Prospectus and the rights issue. The press meeting will be held at: https://youtu.be/qlMJraIRfBo
The subscription period starts on 31 October 2019 and ends on 14 November 2019. The Company will receive SEK 100 million upon full subscription of the Offer Units, before transaction costs. The Investor Warrants have a tenure of 24 months and the Company expects to receive additional net proceeds from the Offering of approximately SEK 300 million upon full subscription and full exercise of the Investor Warrants. The rights issue is also open to the public to the extent not fully subscribed for by existing shareholders.
Expected timetable of principal events
|Publication of the Prospectus||21 October 2019|
|Last day of trading of Existing Shares cum Subscription Rights||25 October 2019|
|First day of trading of Existing Shares ex Subscription Rights||28 October 2019|
|Record Date for allocation of Subscription Rights||29 October 2019|
|Trading Period for Subscription Rights on First North||31 October – 12 November 2019|
|Subscription Period for Offer Units||31 October – 14 November 2019|
|Trading date for BTUs||31 October 2019, until registration of the capital increase|
|Publication of the results of the Offering, expected||19 November 2019|
Investors in the Rights Issue will have possibility to exercise their warrants in five two-week windows during the 24-month period where the warrants can be exercised. The windows will occur in April 2020, September 2020, February 2021, May 2021 and September 2021.
The prospectus is available via the Company’s website (www.oncologyventure.com).
For further information, please contact:
Henrik Moltke, CFO
Telephone +45 53 63 96 37
About Oncology Venture A/S
Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, DRP®. The company has a mature portfolio of seven drug candidates, including compounds in the pre-registration stage.
The current product portfolio includes: 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast cancer; dovitinib, which will enter Phase 2 trials for indications dependent on further Dovitinib-DRP retrospective/prospective analysis of studies completed by Novartis: Ixabepilone for the treatment of breast cancer. LiPlaCis®, a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast and prostate cancer 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; irofulven, a Phase 2 is ongoing for prostate cancer; and APO010, an immuno-oncology product in Phase 1/2 for multiple myeloma.
About the Drug Response Predictor – DRP® Companion Diagnostic
Oncology Venture uses its multi gene DRP® to select those patients who by the genetic signature of their cancer are found to have a high likelihood of responding to the drug. By screening patients before treatment the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology. DRP® is based on messenger RNA from the patient’s biopsies.
DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined.
The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs in the US.
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Svensk Kapitalmarknadsgranskning AB, Email: email@example.com. Tel: +46 11 32 30 732
This information is information that Oncology Venture A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 21, 2019.